Spyre Therapeutics, Inc. (SYRE) - Form 8-K Summary
Business Context and Reporting Period
Spyre Therapeutics, Inc., a Delaware corporation traded on the Nasdaq Global Select Market, filed this Current Report on November 18, 2024. The filing addresses a significant accounting error regarding the calculation of net loss per share and the identification of a material weakness in internal controls over financial reporting.
Key Financial Metrics and Restatement Details
The filing does not report new revenue, profit, cash flow, or debt figures. Instead, it discloses a restatement of net loss per share for Common Stock, Series A Preferred Stock, and Series B Preferred Stock for periods spanning from the three months ended June 30, 2023, through the three months ended September 30, 2024. The error involved the exclusion of Series A and Series B non-voting convertible preferred stock from the two-class method calculation under U.S. GAAP.
| Period | Common Stock (Original) | Common Stock (Restated) | Series A Preferred (Restated) | Series B Preferred (Restated) |
|---|---|---|---|---|
| Three months ended June 30, 2023 | $(56.79) | $(40.14) | $(1,605.58) | N/A |
| Three months ended Sept 30, 2023 | $(9.34) | $(0.86) | $(34.28) | N/A |
| Twelve months ended Dec 31, 2023 | $(49.12) | $(13.76) | $(550.28) | $(550.29) |
| Three months ended March 31, 2024 | $(1.20) | $(0.72) | $(28.93) | $(28.93) |
| Three months ended June 30, 2024 | $(0.86) | $(0.59) | $(23.61) | $(23.61) |
| Three months ended Sept 30, 2024 | $(1.36) | $(1.06) | $(42.22) | $(42.24) |
The company states this matter has no impact on its cash position or other financial data reported outside of net loss per share.
Material Changes and Internal Control Weakness
The Audit Committee concluded that previously issued audited and unaudited financial statements for the affected periods should no longer be relied upon. Management identified a material weakness in internal control over financial reporting specifically related to the lack of effective controls to evaluate the treatment of preferred stock in earnings per share calculations. The company intends to file amendments to its Form 10-K and Form 10-Q reports to correct these figures.
Outlook, Risks, and Management Commentary
Management is committed to remediating the material weakness and anticipates that new controls will be effective once tested for a sufficient period. However, the company warns that failure to remediate could lead to material misstatements, loss of investor confidence, a decline in stock price, and potential delisting from the Nasdaq Global Select Market. The filing includes standard forward-looking statement disclaimers regarding the timing of amendments and the scope of the restatement.
Investor Verification Checklist
- Verify the filing of amended Form 10-K and Form 10-Q reports to confirm the corrected net loss per share figures.
- Monitor the company's progress in remediating the identified material weakness in internal controls.
- Review the impact of the restatement on the company's compliance with Nasdaq listing standards.
- Assess whether the accounting error indicates broader issues in financial reporting processes beyond the EPS calculation.